This article is for marketing, medical affairs and compliance leads at pharmaceutical and medtech companies in India who run, or sign off, content aimed at healthcare professionals. It answers a narrow question: what does the Uniform Code for Pharmaceutical Marketing Practices 2024 allow when the engagement is digital, such as an HCP webinar, a CME invitation on LinkedIn, a sample request by WhatsApp or a speaker video?
A caveat about sources. The Code was notified by the Department of Pharmaceuticals, and we read it through two detailed law-firm summaries because the Department's own PDF would not load for us. Those summaries do not reproduce clause numbers or any digital-specific provision, so where we apply the Code to digital formats below, that is our interpretation, labelled as such. Read the Code itself on the Department of Pharmaceuticals website before you sign off a process, and take legal advice. We are a marketing team, not a law firm.
This article is separate from the rules on influencers. Those sit with the advertising self-regulator ASCI and cover public-facing content. The UCPMP is about a company's dealings with healthcare professionals.
What the Code is, and who it binds
The Department of Pharmaceuticals notified UCPMP 2024 on 12 March 2024. According to Trilegal's analysis, it applies to pharmaceutical companies and medical device manufacturers, and requires industry associations to make sure their members comply, to set up an Ethics Committee for Pharmaceutical Marketing Practices, and to run a UCPMP portal. The same analysis notes that the Code was not issued under a specific parliamentary law, so its legal force is debated, but that the Department expects strict compliance and has signalled a "name and shame" approach. Treat it as binding in practice. Your association membership, your reputation with hospitals and your next audit all depend on it.
What the Code says about promotion
Promotion follows the World Health Assembly's 1988 definition. Promotional material must be consistent with the product's marketing approval, balanced, up to date, verifiable and capable of substantiation, and it must not mislead directly or by implication. For a digital team that translates into four concrete controls: every claim in an e-detail, banner or video carries a reference; the content matches the approved prescribing information; risk information is not buried; and old assets are withdrawn when the approval changes.
Gifts, hospitality, samples and educational items
The detail that matters most to operations teams, again from Trilegal's summary:
- Gifts. Gifts, monetary grants, pecuniary advantages and benefits in kind to healthcare professionals or their family members are prohibited, including through agents, distributors and suppliers.
- Travel and hospitality. These may be extended to event speakers only, not to delegates or attendees.
- Educational items. Items such as books, calendars, diaries, journals and clinical guidelines must be for professional use in healthcare settings, cost no more than INR 1,000 per item and have no independent commercial value.
- Free samples. No more than 12 packs per drug per year, enough for three patients at the prescribed dose, no larger than the smallest commercial pack, and an aggregate value capped at 2% of the company's domestic sales for the year. Companies must keep a system of accountability and control over sample distribution.
The cap on sample value is a company-level control. A team that runs sample requests through a WhatsApp number or an HCP portal needs a ledger that reconciles to it: product, HCP name, quantity, date.
CME, CPD and events
The Code allows companies to run continuing medical education events alone or with professional bodies, with conditions. According to the same analysis, a company must publish on its website how participants and speakers are selected, with a statement of funding and expenditure, and events may not be held at foreign locations. Expenditure follows industry guidelines and the Income Tax Act, and the arrangements are open to audit.
For digital events this has three consequences, which are our reading rather than the text:
- The registration page is a compliance artefact. If the CME is sponsored, the page should show the sponsor, the funding statement and the selection criteria, not just the agenda.
- A virtual event is not a loophole for hospitality. If the invitation offers anything beyond access to the educational content, such as a hamper to delegates, check it against the gifts rule.
- Speaker arrangements stay documented. Fees, travel and the written agreement for a speaker are still subject to the same disclosure and tax rules when the speaker joins from a studio.
Where the NMC notice cuts across the Code
A pharma or medtech marketer can satisfy the UCPMP and still put a doctor in breach of medical ethics. Paragraph 8.1(iv) of the NMC's 6 October 2026 notice says a registered medical practitioner shall not give any approval, recommendation, endorsement, certificate, report or statement about a drug, medicine, device or health product for use in advertising or publicity in connection with their name, signature, photograph, voice or professional status, whether or not money is received. Paragraph 8.1(ii) bars a doctor from permitting the use of their name, image, voice, testimonial or endorsement for the promotion of services or products. Both concern advertising and publicity to the public, not scientific exchange between professionals, but they narrow what a doctor can safely appear in.
For brand teams, the practical effect is that "doctor says" content must be designed as education, not endorsement. A speaker presenting clinical evidence at a CME is different from the same doctor appearing in a product-branded video that the company then boosts. Have your legal team review that boundary for every doctor-fronted asset, and keep the doctors' own advice in the loop. Our overview of the 2026 NMC rules lists the other restrictions that touch doctors.




